Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Docosahexaenoic acid for nonalcoholic fatty liver disease in children
2012-001975-36Phase 4Active
- Sponsor
- Azienda Ospedaliero-Universitaria Policlinico Umberto I
- Start
- Jun 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of docosahexaenoic acid in metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH), sponsored by Azienda Ospedaliero-Universitaria Policlinico Umberto I. Primary endpoint: Reduction of hepatic fat content. Started Jun 2012; status: active.
02
Drugs
docosahexaenoic acid
03
Conditions
metabolic dysfunction-associated steatotic liver disease (MASLD)metabolic dysfunction-associated steatohepatitis (MASH)
Beyond the preview
Go deeper on 2012-001975-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-001975-36.